المؤلفون: Stéphan Juergen Harbarth, Christophe Jaccard, Bara Ricou, D. Aymon, Nicolas Troillet, Jacques-André Romand, Jacques Bille, Patrick Ambrosetti, Giorgio Zanetti, Daniel Pablo Lew, M. P. Glauser, Olivier Huber, A. Cometta, G. Praz, René Chioléro, R. Schneider

المصدر: Antimicrobial Agents and Chemotherapy, Vol. 42, No 11 (1998) pp. 2966-2972

مصطلحات موضوعية: Male, Cilastatin, Imipenem Drug Combination, Penicillanic Acid, Cilastatin/therapeutic use, Piperacillin/ therapeutic use, polycyclic compounds, Pharmacology (medical), Prospective Studies, Antibacterial agent, ddc:616, Cross Infection, Imipenem/cilastatin, Drug Therapy, Combination/ therapeutic use, Middle Aged, Imipenem/therapeutic use, Drug Combinations, Infectious Diseases, Cilastatin, Pseudomonas Infections/drug therapy, Acute Disease, Piperacillin/tazobactam, Drug Therapy, Combination, Female, lipids (amino acids, peptides, and proteins), medicine.drug, Adult, Tazobactam, medicine.medical_specialty, Peritonitis/ drug therapy, Peritonitis, Clinical Therapeutics, Cross Infection/ drug therapy, Internal medicine, medicine, Humans, Pseudomonas Infections, Aged, Piperacillin, Pharmacology, Errata, business.industry, Penicillanic Acid/ analogs & derivatives/therapeutic use, Pneumonia/ drug therapy, Pneumonia, biochemical phenomena, metabolism, and nutrition, bacterial infections and mycoses, medicine.disease, Surgery, Imipenem, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::409e650079991a3321d180c52e940800
https://europepmc.org/articles/PMC89196/